Cereno Scientific to present preclinical data for drug candidate CS585 at the EHA 2024 Hybrid Congress
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular disease, today announced that an abstract on the preclinical drug candidate, novel IP receptor agonist CS585 has been accepted and will be presented at the EHA 2024 Hybrid Congress, in Madrid, June 13–16, 2024.The abstract titled “Superior Selectivity of CS585 to The Prostacyclin Receptor Translates to A New Viable Target for Prevention of Thrombosis”, was authored by L. Stanger, P Yalavarthi, A. Rickenberg, K. Goerger, D. Gilmore and M. Holinstat, at